USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Sarah currently serves as the Chief Financial Officer and Principal Accounting Officer for Criteo S.A.
Subscribe To Our Newsletter & Stay Updated